Sanofi defends Dupixent patents, but execs insist it has nothing to do with CEO change

BioSpace

Sanofi’s interim leadership sought on a Thursday earnings call to quell concerns that its sudden defense of Dupixent’s patents had anything to do with the departure of CEO Paul Hudson.

CommercialImmunology & InflammationRead full story